Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Net Margin (2023 - 2025)

Historic Net Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2737.3%.

  • Entrada Therapeutics' Net Margin fell 26658000.0% to 2737.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 168.32%, marking a year-over-year decrease of 1938700.0%. This contributed to the annual value of 31.12% for FY2024, which is 362700.0% up from last year.
  • Entrada Therapeutics' Net Margin amounted to 2737.3% in Q3 2025, which was down 26658000.0% from 2211.54% recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Net Margin high stood at 81.09% for Q3 2023, and its period low was 2737.3% during Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median Net Margin value was 26.62% (recorded in 2023), while the average stood at 464.99%.
  • As far as peak fluctuations go, Entrada Therapeutics' Net Margin skyrocketed by 2007700bps in 2024, and later tumbled by -26658000bps in 2025.
  • Quarter analysis of 3 years shows Entrada Therapeutics' Net Margin stood at 22.7% in 2023, then soared by 113bps to 2.95% in 2024, then crashed by -92742bps to 2737.3% in 2025.
  • Its Net Margin was 2737.3% in Q3 2025, compared to 2211.54% in Q2 2025 and 84.39% in Q1 2025.